Nanoscope Therapeutics has selected InspiroGene by McKesson to provide US commercialization services for its lead product candidate, Mogenry, pending regulatory approval in the United States.

Under the agreement, InspiroGene by McKesson will provide specialty pharmacy, specialty distribution, and patient hub services to support the anticipated launch of Nanoscope’s retinal therapy in the US market. According to Nanoscope, the collaboration is intended to streamline commercialization and supply chain operations while helping deliver patient and provider support services as the company prepares for a potential commercial launch.

Mogenry is being developed as what Nanoscope describes as the first optogenetic gene therapy intended for the US market. The therapy is designed for patients with retinal degenerative diseases, including retinitis pigmentosa, a group of inherited disorders that can lead to progressive vision loss and blindness. Nanoscope's technology platform is designed to restore vision without requiring a surgical implant or light-intensifying device, potentially simplifying treatment administration in specialty care settings.

“Engaging with InspiroGene is an important step in our commercialization readiness planning,” said Sulagna Bhattacharya, CEO of Nanoscope Therapeutics. “InspiroGene’s experience in full-service patient support and its expertise across the U.S. healthcare system position them well to support efficient product delivery following regulatory approval.”